Artios Pharma Limited

Artios Pharma is a biotechnology company focused on DNA Damage Response (DDR)-based therapeutics for cancer. It was founded by industry-leading experts who pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is advancing a pipeline of product candidates with first- and best-in-class potential, including alnodesertib (ATR inhibitor) and ART6043 (Polθ inhibitor).

Artios Pharma is a company in Cambridge, United Kingdom. It was founded by industry-leading experts having pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is focused on DNA Damage Response (DDR)-based therapeutics for cancer.

• alnodesertib

  ATR inhibitor

• ART6043

  Polθ inhibitor

• 2021.11.16

  Reported2021.11.16

  Artios appoints Nora Brennan to its board and as audit committee chair[5]Artios任命Nora Brennan为董事会成员及审计委员会主席menafn.com

  Artios Pharma Limited announced Nora Brennan’s appointment to its Board of Directors, where she will serve as Chair of the Audit Committee.

Read more

1. 1DNA Damage Response | DDR Company | Artios Pharmaartios.com
2. 2About Artios | Leadership | Scientific Advisors | Boardartios.com
3. 3ESG - Artios Pharmaartios.com
4. 4Artios Pharma Limited (United Kingdom)wikidata.org
5. 5Artios任命Nora Brennan为董事会成员及审计委员会主席menafn.com